164 related articles for article (PubMed ID: 32850364)
21. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.
Khan SN; Jankowska AM; Mahfouz R; Dunbar AJ; Sugimoto Y; Hosono N; Hu Z; Cheriyath V; Vatolin S; Przychodzen B; Reu FJ; Saunthararajah Y; O'Keefe C; Sekeres MA; List AF; Moliterno AR; McDevitt MA; Maciejewski JP; Makishima H
Leukemia; 2013 Jun; 27(6):1301-9. PubMed ID: 23486531
[TBL] [Abstract][Full Text] [Related]
22. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.
Song X; Zhang L; Gao T; Ye T; Zhu Y; Lei Q; Feng Q; He B; Deng H; Yu L
Biomed Pharmacother; 2016 Jul; 81():288-294. PubMed ID: 27261606
[TBL] [Abstract][Full Text] [Related]
23. Deletion of Polycomb Repressive Complex 2 From Mouse Intestine Causes Loss of Stem Cells.
Koppens MA; Bounova G; Gargiulo G; Tanger E; Janssen H; Cornelissen-Steijger P; Blom M; Song JY; Wessels LF; van Lohuizen M
Gastroenterology; 2016 Oct; 151(4):684-697.e12. PubMed ID: 27342214
[TBL] [Abstract][Full Text] [Related]
24. Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons.
Henriquez B; Bustos FJ; Aguilar R; Becerra A; Simon F; Montecino M; van Zundert B
Mol Cell Neurosci; 2013 Nov; 57():130-43. PubMed ID: 23932971
[TBL] [Abstract][Full Text] [Related]
25. Aberrant differential expression of EZH1 and EZH2 in Polycomb repressive complex 2 among B- and T/NK-cell neoplasms.
Abdalkader L; Oka T; Takata K; Sato H; Murakami I; Otte AP; Yoshino T
Pathology; 2016 Aug; 48(5):467-82. PubMed ID: 27311868
[TBL] [Abstract][Full Text] [Related]
26. EZH2 variants differentially regulate polycomb repressive complex 2 in histone methylation and cell differentiation.
Mu W; Starmer J; Yee D; Magnuson T
Epigenetics Chromatin; 2018 Dec; 11(1):71. PubMed ID: 30522506
[TBL] [Abstract][Full Text] [Related]
27. Clinical Correlations of Polycomb Repressive Complex 2 in Different Tumor Types.
Erokhin M; Chetverina O; Győrffy B; Tatarskiy VV; Mogila V; Shtil AA; Roninson IB; Moreaux J; Georgiev P; Cavalli G; Chetverina D
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34202528
[TBL] [Abstract][Full Text] [Related]
28. EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.
Li B; Chng WJ
J Hematol Oncol; 2019 Nov; 12(1):118. PubMed ID: 31752930
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of Enhancer of Zeste Homolog 2 (EZH2) with Associated pERK Co-Expression and PRC2 Complex Protein SUZ12 Correlation in Adult T-Cell Leukemia/Lymphoma.
Chai J; Choudhuri J; Gong JZ; Wang Y; Tian X
Cancers (Basel); 2024 Feb; 16(3):. PubMed ID: 38339397
[TBL] [Abstract][Full Text] [Related]
30. HIFI-α activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer.
Mahara S; Lee PL; Feng M; Tergaonkar V; Chng WJ; Yu Q
Proc Natl Acad Sci U S A; 2016 Jun; 113(26):E3735-44. PubMed ID: 27303043
[TBL] [Abstract][Full Text] [Related]
31. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
32. Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation.
Gannon OM; Merida de Long L; Endo-Munoz L; Hazar-Rethinam M; Saunders NA
Clin Cancer Res; 2013 Jan; 19(2):428-41. PubMed ID: 23186778
[TBL] [Abstract][Full Text] [Related]
33. Snail2/Slug cooperates with Polycomb repressive complex 2 (PRC2) to regulate neural crest development.
Tien CL; Jones A; Wang H; Gerigk M; Nozell S; Chang C
Development; 2015 Feb; 142(4):722-31. PubMed ID: 25617436
[TBL] [Abstract][Full Text] [Related]
34. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).
Yang CY; Wang S
J Med Chem; 2017 Mar; 60(6):2212-2214. PubMed ID: 28256832
[TBL] [Abstract][Full Text] [Related]
35. Targeting histone methyltransferase EZH2 as cancer treatment.
Kondo Y
J Biochem; 2014 Nov; 156(5):249-57. PubMed ID: 25179367
[TBL] [Abstract][Full Text] [Related]
36. [EZH inhibitors in lymphoma therapy].
Ishitsuka K
Rinsho Ketsueki; 2023; 64(7):665-669. PubMed ID: 37544728
[TBL] [Abstract][Full Text] [Related]
37. Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation.
Zhou Z; Gao J; Popovic R; Wolniak K; Parimi V; Winter JN; Licht JD; Chen YH
Leuk Lymphoma; 2015; 56(10):2895-901. PubMed ID: 25651430
[TBL] [Abstract][Full Text] [Related]
38. Combination Treatment with GSK126 and Pomalidomide Induces B-Cell Differentiation in
Park S; Jo SH; Kim JH; Kim SY; Ha JD; Hwang JY; Lee MY; Kang JS; Han TS; Park SG; Kim S; Park BC; Kim JH
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32906688
[TBL] [Abstract][Full Text] [Related]
39. An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED.
Qi W; Zhao K; Gu J; Huang Y; Wang Y; Zhang H; Zhang M; Zhang J; Yu Z; Li L; Teng L; Chuai S; Zhang C; Zhao M; Chan H; Chen Z; Fang D; Fei Q; Feng L; Feng L; Gao Y; Ge H; Ge X; Li G; Lingel A; Lin Y; Liu Y; Luo F; Shi M; Wang L; Wang Z; Yu Y; Zeng J; Zeng C; Zhang L; Zhang Q; Zhou S; Oyang C; Atadja P; Li E
Nat Chem Biol; 2017 Apr; 13(4):381-388. PubMed ID: 28135235
[TBL] [Abstract][Full Text] [Related]
40. EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma.
Hübner JM; Müller T; Papageorgiou DN; Mauermann M; Krijgsveld J; Russell RB; Ellison DW; Pfister SM; Pajtler KW; Kool M
Neuro Oncol; 2019 Jul; 21(7):878-889. PubMed ID: 30923826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
